{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:53:52Z","timestamp":1785358432976,"version":"3.55.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>We aimed to assess the prognostic value of baseline tumor burden and dissemination parameters extracted from <jats:sup>18<\/jats:sup>F-FDG PET\/CT in patients with early or advanced Hodgkin lymphoma (HL) treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or escalated BEACOPP (increased bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Patients aged \u226518 years with classical Hodgkin lymphoma were retrospectively included. Progression-free survival (PFS) analysis of dichotomized clinicobiological and PET\/CT parameters (SUV<jats:sub>max<\/jats:sub>, TMTV, TLG, D<jats:sub>max<\/jats:sub>, and D<jats:sub>bulk<\/jats:sub>) was performed. Optimal cutoff values for quantitative metrics were defined as the values maximizing the Youden index from receiver operating characteristic analysis. PFS rates were estimated with Kaplan-Meier curves, and the log-rank test was used to assess statistical significance. Hazard ratios were calculated using Cox proportional hazards models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>With a median age of 32 years, 166 patients were enrolled. A total of 111 patients had ABVD or ABVD-like treatment with or without radiotherapy and 55 patients with escalated BEACOPP treatment. The median follow-up was 55 months. Only International Prognostic Score (IPS &gt;1), TMTV &gt;107 cm<jats:sup>3<\/jats:sup>, and TLG &gt;1628 were found to be significant prognostic factors for PFS on univariate analysis. Multivariate analysis revealed that IPS and TLG were independently prognostic and, combined, identified 4 risk groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001): low (low TLG and low IPS; 4-year PFS, 95%), intermediate-low (high IPS and low TLG; 4-year PFS, 79%), intermediate-high (low IPS and high TLG; 4-year PFS, 78%), and high (high TLG and high IPS; 4-year PFS, 71%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Combining baseline TLG with IPS could improve PFS prediction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004930","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T15:53:00Z","timestamp":1701186780000},"page":"e1-e5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18F-FDG PET\/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma"],"prefix":"10.1097","volume":"49","author":[{"given":"Mehdi","family":"Mouheb","sequence":"first","affiliation":[{"name":"Univ Rennes, CLCC Eug\u00e8ne Marquis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Pierre-Jean","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU de Rennes, INSERM, LTSI-UMR 1099, Rennes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Devillers","sequence":"additional","affiliation":[{"name":"Univ Rennes, CLCC Eug\u00e8ne Marquis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ferm\u00e9","sequence":"additional","affiliation":[{"name":"CLCC Gustave Roussy, Villejuif"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Benchalal","sequence":"additional","affiliation":[{"name":"Univ Rennes, CLCC Eug\u00e8ne Marquis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Manson","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU de Rennes, INSERM, MOBIDIC-UMR 1236, Rennes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Le Jeune","sequence":"additional","affiliation":[{"name":"Univ Rennes, CLCC Eug\u00e8ne Marquis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU de Rennes, INSERM, MOBIDIC-UMR 1236, Rennes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Palard-Novello","sequence":"additional","affiliation":[{"name":"Univ Rennes, CLCC Eug\u00e8ne Marquis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"bib5-20250621","first-page":"262","article-title":"Update of the recommendations of good clinical practice for the use of PET in oncology [in French]","volume":"106","year":"2019","journal-title":"Bull Cancer"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.122.264740","article-title":"Prognostic value of 18F-FDG PET\/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2967\/jnumed.121.263501","article-title":"18F-FDG PET maximum-intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic value of baseline total metabolic tumor volume measured on FDG PET in patients with Richter syndrome","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.3390\/jcm10194396","article-title":"Total lesion glycolysis improves tumor burden evaluation and risk assessment at diagnosis in Hodgkin lymphoma","volume":"10","year":"2021","journal-title":"J Clin Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"11073","DOI":"10.1038\/s41598-019-47453-5","article-title":"Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin lymphoma\u2014data from the prospective, multicenter phase III HD16 trial","volume":"22","year":"2022","journal-title":"BMC Cancer"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"23195","DOI":"10.1038\/s41598-021-02734-w","article-title":"Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin\u2019s lymphoma","volume":"11","year":"2021","journal-title":"Sci Rep"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/cas.12282","article-title":"Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin\u2019s lymphoma","volume":"104","year":"2013","journal-title":"Cancer Sci"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.21.01228","article-title":"First extensive analysis of 18F-labeled fluorodeoxyglucose positron emission tomography\u2013computed tomography in a large cohort of patients with HIV-associated Hodgkin lymphoma: baseline total metabolic tumor volume affects prognosis","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","article-title":"High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline","volume":"107","year":"2022","journal-title":"Haematologica"},{"key":"bib19-20250621","first-page":"913866","article-title":"Healthy organs uptake on baseline 18F-FDG PET\/CT as an alternative to total metabolic tumor volume to predict event-free survival in classical Hodgkin\u2019s lymphoma","volume":"9","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood-2021-147177","article-title":"Total metabolic tumor volume and tumor dissemination are independent prognostic factors in advanced Hodgkin lymphoma","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib21-20250621","first-page":"207","article-title":"Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma","volume":"60","year":"2018","journal-title":"J Nucl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT","volume":"32","year":"2021","journal-title":"Ann Oncol"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hon.3025","article-title":"Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine\u2013treated, interimPET-negative classical Hodgkin lymphoma patients: a radio-genomic study","volume":"40","year":"2022","journal-title":"Hematol Oncol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00259-022-06086-z","article-title":"Dissemination patterns of Hodgkin lymphoma using a probability network model based on [18F]-FDG PET\/CT","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:04:06Z","timestamp":1750532646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004930","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}